Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma Patients

Benzinga Newsdesk www.benzinga.com Positive 59.3%

Neg 0% Neu 0% Pos 59.3%

The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.